UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism

The New England journal of medicine, 2013-10, Vol.369 (15), p.1406-1415

2013

Volltextzugriff (PDF)

Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism

The New England journal of medicine, 2018-02, Vol.378 (7), p.615-624

2018

Volltextzugriff (PDF)

Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation–Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF–TIMI 48)

The American heart journal, 2010-10, Vol.160 (4), p.635-641.e2

2010

Volltextzugriff (PDF)

Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial

The Lancet (British edition), 2015-06, Vol.385 (9984), p.2288-2295

2015

Volltextzugriff (PDF)

Edoxaban versus Warfarin in Patients with Atrial Fibrillation

The New England journal of medicine, 2013-11, Vol.369 (22), p.2093-2104

2013

Volltextzugriff (PDF)

Effects of Food on the Pharmacokinetics of Edoxaban, an Oral Direct Factor Xa Inhibitor, in Healthy Volunteers

Journal of clinical pharmacology, 2011-05, Vol.51 (5), p.687-694

2011

Volltextzugriff (PDF)

Left atrial structure and function in atrial fibrillation: ENGAGE AF-TIMI 48

European heart journal, 2014-06, Vol.35 (22), p.1457-1465

2014

Volltextzugriff (PDF)

Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation

Thrombosis and haemostasis, 2012-05, Vol.107 (5), p.925-934

2012

Volltextzugriff (PDF)

Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study

Thrombosis and haemostasis, 2010-09, Vol.104 (3), p.642-649

2010

Volltextzugriff (PDF)

The Effects of the Antiplatelet Agents, Aspirin and Naproxen, on Pharmacokinetics and Pharmacodynamics of the Anticoagulant Edoxaban, a Direct Factor Xa Inhibitor

Journal of cardiovascular pharmacology, 2013-08, Vol.62 (2), p.212-221

2013

Volltextzugriff (PDF)

Edoxaban drug–drug interactions with ketoconazole, erythromycin, and cyclosporine

British journal of clinical pharmacology, 2016-12, Vol.82 (6), p.1591-1600

2016

Volltextzugriff (PDF)

Drug-Drug Interaction Studies of Cardiovascular Drugs Involving P-Glycoprotein, an Efflux Transporter, on the Pharmacokinetics of Edoxaban, an Oral Factor Xa Inhibitor

American journal of cardiovascular drugs : drugs, devices, and other interventions, 2013-10, Vol.13 (5), p.331-342

2013

Volltextzugriff (PDF)

Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score

European heart journal, 2023-04, Vol.44 (14), p.1231-1244

2023

Volltextzugriff (PDF)

Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial

European heart journal, 2019-05, Vol.40 (19), p.1541-1550

2019

Volltextzugriff (PDF)

Edoxaban versus Warfarin in Patients with Atrial Fibrillation at the Extremes of Body Weight: An Analysis from the ENGAGE AF-TIMI 48 Trial

Thrombosis and haemostasis, 2021-02, Vol.121 (2), p.140-149

2021

Volltextzugriff (PDF)

A randomized trial of the safety, pharmacokinetics and pharmacodynamics of edoxaban, an oral factor Xa inhibitor, following a switch from warfarin

British journal of clinical pharmacology, 2013-04, Vol.75 (4), p.966-978

2013

Volltextzugriff (PDF)

Edoxaban Versus standard of care and their effects on clinical outcomes in patients having undergone Transcatheter Aortic Valve Implantation in Atrial Fibrillation—Rationale and design of the ENVISAGE-TAVI AF trial

The American heart journal, 2018-11, Vol.205, p.63-69

2018

Volltextzugriff (PDF)

Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48

European journal of heart failure, 2016-09, Vol.18 (9), p.1153-1161

2016

Volltextzugriff (PDF)

Edoxaban Versus Warfarin Stratified by Average Blood Pressure in 19 679 Patients With Atrial Fibrillation and a History of Hypertension in the ENGAGE AF-TIMI 48 Trial

Hypertension (Dallas, Tex. 1979), 2019-09, Vol.74 (3), p.597-605

2019

Volltextzugriff (PDF)

Pharmacokinetics of the direct factor Xa inhibitor edoxaban and digoxin administered alone and in combination

Journal of cardiovascular pharmacology, 2012-10, Vol.60 (4), p.335

2012

Volltextzugriff (PDF)

Pharmacokinetics of the Direct Factor Xa Inhibitor Edoxaban and Digoxin Administered Alone and in Combination

Journal of cardiovascular pharmacology, 2012-10, Vol.60 (4), p.335-341

2012

Volltextzugriff (PDF)

Inhibition of thrombin-activatable fibrinolysis inhibitor via DS-1040 to accelerate clot lysis in patients with acute pulmonary embolism: a randomized phase 1b study

Journal of thrombosis and haemostasis, 2023-10, Vol.21 (10), p.2929-2940

2023

Volltextzugriff (PDF)

Long‐term risk of recurrent venous thromboembolism among patients receiving extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and meta‐analysis

Journal of thrombosis and haemostasis, 2021-11, Vol.19 (11), p.2801-2813

2021

Volltextzugriff (PDF)

Edoxaban Exposure in Patients With Atrial Fibrillation and Estimated Creatinine Clearance Exceeding 100 mL/min

Clinical pharmacology in drug development, 2022-05, Vol.11 (5), p.666-674

2022

Volltextzugriff (PDF)

Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation

European heart journal, 2015-06, Vol.36 (23), p.1470-1477

2015

Volltextzugriff (PDF)

1 – 25 von 37

Suche als RSS-Feed

Aktive Filter

KollektionRCN full-text journals@Ovid

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(35)
Mit Volltextzugriff
(31)

Publikationsform

Artikel
(37)

Sprache

Englisch
(36)
Russisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism

Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism

Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation–Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF–TIMI 48)

Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial

Edoxaban versus Warfarin in Patients with Atrial Fibrillation

Effects of Food on the Pharmacokinetics of Edoxaban, an Oral Direct Factor Xa Inhibitor, in Healthy Volunteers

Left atrial structure and function in atrial fibrillation: ENGAGE AF-TIMI 48

Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation

Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study

The Effects of the Antiplatelet Agents, Aspirin and Naproxen, on Pharmacokinetics and Pharmacodynamics of the Anticoagulant Edoxaban, a Direct Factor Xa Inhibitor

Edoxaban drug–drug interactions with ketoconazole, erythromycin, and cyclosporine

Drug-Drug Interaction Studies of Cardiovascular Drugs Involving P-Glycoprotein, an Efflux Transporter, on the Pharmacokinetics of Edoxaban, an Oral Factor Xa Inhibitor

Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score

Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial

Edoxaban versus Warfarin in Patients with Atrial Fibrillation at the Extremes of Body Weight: An Analysis from the ENGAGE AF-TIMI 48 Trial

A randomized trial of the safety, pharmacokinetics and pharmacodynamics of edoxaban, an oral factor Xa inhibitor, following a switch from warfarin

Edoxaban Versus standard of care and their effects on clinical outcomes in patients having undergone Transcatheter Aortic Valve Implantation in Atrial Fibrillation—Rationale and design of the ENVISAGE-TAVI AF trial

Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48

Edoxaban Versus Warfarin Stratified by Average Blood Pressure in 19 679 Patients With Atrial Fibrillation and a History of Hypertension in the ENGAGE AF-TIMI 48 Trial

Pharmacokinetics of the direct factor Xa inhibitor edoxaban and digoxin administered alone and in combination

Pharmacokinetics of the Direct Factor Xa Inhibitor Edoxaban and Digoxin Administered Alone and in Combination

Inhibition of thrombin-activatable fibrinolysis inhibitor via DS-1040 to accelerate clot lysis in patients with acute pulmonary embolism: a randomized phase 1b study

Long‐term risk of recurrent venous thromboembolism among patients receiving extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and meta‐analysis

Edoxaban Exposure in Patients With Atrial Fibrillation and Estimated Creatinine Clearance Exceeding 100 mL/min

Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation

Aktive Filter

Suchergebnisse filtern